This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a double-blind, randomised controlled trial that was conducted in a single centre. The randomisation was performed using sealed envelopes. All patients, carers and assessors were blinded to the treatment. The duration of follow-up was one year. The patients were assessed at baseline, after 15 and 30 treatments, at 6 weeks, 6 months and 1 year. Two patients withdrew during the course of the study (one in each group).
Analysis of effectiveness
The basis of the analysis was treatment completers only. The primary health outcome was the ulcer surface area measurement (using a special software program, SigmaScan) at 6 weeks after the end of the intervention. The ulcer assessment also included a measurement of ulcer depth and a visual examination for clinical signs of infection. Quality of life was measured using the generic form SF-36 and the Hospital Anxiety and Depression Scale (HAD scale). The patients were comparable at inclusion.
Effectiveness results
At the 1-year follow-up, complete healing was achieved in 5 of the 8 ulcers in the treatment group and in none of the 8 ulcers in the control group, (p=0.026, Fisher's exact).
At the 6-week follow-up, the median decrease of the wound areas was 100% (range: 34 -100) in the treatment group and 52% (range: -29 -100) in the control group, (p=0.027, Mann-Whitney). However, at the 6-month follow-up, the values were 100% (range: -206 -100) in the treatment group and 95% (range: 0 -100) in the control group. This difference was not statistically significant.
Patients in both the treatment and control groups showed a significant improvement in the depression score on the HAD scale.
Only the control group had a significant reduction in their anxiety score, (p=0.042, Wilcoxon).
The SF-36 scores showed only a significant improvement in the general health (p=0.012, Wilcoxon) and vitality (p=0.018, Wilcoxon) domains in the treatment group. However, there was no significant difference between the groups in the other domains and for all the domains together.
Clinical conclusions
Hyperbaric oxygen has the potential to enhance the healing of ischaemic diabetic lower-extremity ulcers. The lack of a significant difference between the groups in terms of physical functioning was surprising, and suggests that the ulcers largely did not limit their physical functioning.
Measure of benefits used in the economic analysis
There was no summary measure of benefit. A cost-consequences analysis was therefore conducted.
Direct costs
The cost/resource boundary was that of the hospital. The direct costs were for the inpatient and outpatient hospital visits for ulcer dressing, hyperbaric oxygen treatment, and the treatment of any complications. The costs of an outpatient hospital visit for ulcer dressing were obtained from the NHS Executive 2000 costs for the UK. Discounting was unnecessary since all the costs were incurred in 12 months. The costs and the quantities were not reported separately. The cost of treatment was derived from the Hull Hyperbaric Unit.
The perspective adopted was not reported, but it was likely to have been that of the hospital. The major direct costs seem to have been included. Although the indirect costs were not included, it is unlikely that they would affect the authors' conclusions since they should be common to both alternatives. The price year was reported, which helps the generalisability of the results. However, the costs and the quantities were not reported separately. No statistical or sensitivity analyses of the costs or quantities were performed. Discounting was unnecessary since the costs were incurred in one year.
Other issues
The generalisability of the results was not specifically discussed. Adequate comparisons were made with studies dealing with the same topic. The study enrolled patients with ischaemic non-healing diabetic lower-extremity ulcers and this was reflected in the authors' conclusions. The authors reported limitations of their study, which have been highlighted already. The authors acknowledged that a disease-specific quality of life measure might have been more appropriate.
